AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam NanoTab For Procedural Sedation, Anxiolysis & Analgesia
AcelRx Pharmaceuticals, Inc. announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet need for a non-invasive product to provide mild sedation, anxiolysis and analgesia with rapid onset of action for the increasing number of painful and anxiety-producing office-based procedures.
Related Posts
Tags: acelrx, analgesia, anxiolysis, nanotab, phase, positive, procedural, results, sedation, study, sufentaniltriazolam
This entry was posted on Saturday, October 24th, 2009 at 10:10 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
